Pharma-Bio Serv, Inc. (PBSV) stock
PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31
$0.48+0.08 (+20.00%)
Close on Oct 19, 2026Market cap $11.00MP/E 48.0Yield –
Pharma-Bio Serv gross margin
Gross margin is gross profit as a percentage of revenue.
Pharma-Bio Serv's gross margin for the twelve months ending Jul 31, 2026 was 32.3%. For fiscal 2025 it was 32.3%, against 26.5% the year before. The highest annual figure on record is 35.8% in fiscal 2013.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 32.3% | +5.9 |
| FY2024 | Oct 31, 2024 | 26.5% | −3.4 |
| FY2023 | Oct 31, 2023 | 29.8% | +4.7 |
| FY2022 | Oct 31, 2022 | 25.2% | −1.5 |
| FY2021 | Oct 31, 2021 | 26.6% | −4.3 |
| FY2020 | Oct 31, 2020 | 30.9% | −0.7 |
| FY2019 | Oct 31, 2019 | 31.7% | −0.3 |
| FY2018 | Oct 31, 2018 | 32.0% | +3.1 |
| FY2017 | Oct 31, 2017 | 28.9% | −0.7 |
| FY2016 | Oct 31, 2016 | 29.6% | −2.4 |
| FY2015 | Oct 31, 2015 | 32.0% | −0.6 |
| FY2014 | Oct 31, 2014 | 32.6% | −3.2 |
| FY2013 | Oct 31, 2013 | 35.8% | +2.0 |
| FY2012 | Oct 31, 2012 | 33.8% | −0.6 |
| FY2011 | Oct 31, 2011 | 34.4% | +4.5 |
| FY2010 | Oct 31, 2010 | 29.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | 29.6% | +0.4 |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | 33.4% | −0.5 |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | 31.5% | +0.4 |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | 34.8% | +3.7 |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | 29.3% | +3.0 |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | 33.9% | +7.9 |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | 31.1% | +8.6 |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | 31.1% | +5.3 |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | 26.3% | −7.6 |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | 26.0% | −3.5 |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | 22.5% | −6.8 |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | 25.8% | +0.3 |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | 33.9% | +7.1 |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | 29.5% | +4.3 |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | 29.3% | +3.7 |
| Q1 FY2022CQ4 2021 | Jul 31, 2022 | 25.6% | −3.7 |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | 26.8% | −0.2 |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | 25.2% | −4.4 |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | 25.6% | −7.5 |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | 29.3% | −5.1 |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | 27.0% | −4.9 |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | 29.5% | −2.0 |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | 33.1% | +2.2 |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | 34.4% | +2.0 |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | 31.9% | −1.1 |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | 31.5% | −2.9 |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | 30.9% | +3.4 |
| Q1 FY2019CQ4 2018 | Jan 31, 2019 | 32.4% | +0.7 |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | 33.0% | −29.2 |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | 34.4% | +11.1 |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | 27.5% | +1.0 |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | 31.7% | +6.2 |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | 62.3% | +39.1 |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | 23.3% | −6.0 |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | 26.6% | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | 25.5% | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | 23.2% | – |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | 29.3% | – |
See a number that looks wrong?